vTv Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
VTVT Nasdaq 2830 vtvtherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for vTv Therapeutics Inc.

All You Need to Know About vTv Therapeutics (VTVT) Rating Upgrade to Buy - Nov 11th, 2025 10:00 am
VTv Therapeutics: Q3 Earnings Snapshot - Nov 6th, 2025 3:42 pm
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 6th, 2025 2:15 pm
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board - Oct 9th, 2025 6:00 am
vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting - Sep 15th, 2025 6:00 am
UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences - Sep 3rd, 2025 2:57 pm
vTv Therapeutics to Participate in Upcoming September Investor Conferences - Sep 3rd, 2025 6:00 am
vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund - Sep 2nd, 2025 6:00 am
VTv Therapeutics: Q2 Earnings Snapshot - Aug 12th, 2025 2:53 pm
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Aug 12th, 2025 2:15 pm
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin - Aug 11th, 2025 6:00 am
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes - Aug 7th, 2025 6:00 am
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series - Jun 11th, 2025 6:00 am
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin - May 19th, 2025 7:00 am
VTv Therapeutics: Q1 Earnings Snapshot - May 15th, 2025 2:19 pm
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update - May 15th, 2025 2:01 pm
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes - May 15th, 2025 10:00 am
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics - Mar 21st, 2025 2:46 am
VTv Therapeutics: Q4 Earnings Snapshot - Mar 20th, 2025 4:00 pm
vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - Mar 20th, 2025 3:35 pm